After Cowen & Co. and Needham gave Intercept Pharma (NASDAQ: ICPT) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Jay Olson maintained a Buy rating on Intercept Pharma today. The company’s shares opened today at $111.97.
According to TipRanks.com, Olson has 0 stars on 0-5 star ranking scale with an average return of -2.6% and a 45.0% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Enanta Pharmaceuticals.
Currently, the analyst consensus on Intercept Pharma is a Strong Buy with an average price target of $164, a 46.5% upside from current levels. In a report issued on March 5, Wedbush also reiterated a Buy rating on the stock with a $251 price target.
See today’s analyst top recommended stocks >>
Based on Intercept Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $88.01 million. In comparison, last year the company had a GAAP net loss of $111 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
Read More on ICPT:
